NRF2 is a member of the cap n collar (CNC)-bZip transcription factor family that upon recognition of the antioxidant response cis element (ARE) heterodimerizes with small musculoaponeurotic fibrosarcoma (sMAF) proteins to activate transcription (Igarashi et al, 1994
Results vary, but some people report milder side effects with tirzepatide
This method focuses on improved tolerance, and sustainable outcomes while supporting healthy metabolic function
An international consensus now defines MAFLD through steatosis and diabetes/obesity or two metabolic abnormalities
Semaglutide and tirzepatide allow for albumin binding and resistance to DPP4 degradation, creating a significantly longer half-life (5 days for tirzepatide and 7 days for semaglutide) and thus a greater effect on receptors and downstream pathways in the central nervous, cardiovascular, digestive, and musculoskeletal systems as described below [37, 38]